97 articles about InflaRx
InflaRx Reports Q1 2020 Financial & Operating Results
End of Phase II meeting with the FDA scheduled to discuss the path forward for IFX-1 in Hidradenitis Suppurativa Initial promising results reported in Pyoderma Gangraenosum Part 1 of adaptive randomized trial in severe COVID-19 pneumonia fully enrolled Signed clinical collaboration agreement in oncology Cash, cash equivalents and financial assets of approximately €108.0 million as of March 31, 2020 JENA, Germany, May 21, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage
InflaRx Reports Full Year 2019 Financial & Operating Results
End of Phase 2 FDA meeting scheduled to discuss the path forward for IFX-1 in Hidradenitis Suppurativa Initial promising results reported in Pyoderma Gangraenosum Part 1 of adaptive randomized trial in severe COVID-19 pneumonia fully enrolled Executed clinical collaboration agreement in oncology with Merck & Co, Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada) Senior executives hired for key positions Cash, cash equivalents and financial assets were €115.8 million as o
InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology
InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the Netherlands
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
Two out of the first five patients dosed with IFX-1 achieved complete remission Dose escalation warranted by pharmacodynamic analysis and approved by relevant authorities for a total enrollment of 18 patients in 3 dose cohorts InflaRx to present initial data at the SVB Leerink Global Healthcare Conference today at 9:00 am EST (3:00 pm CET). JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory t
InflaRx to Present at Upcoming J.P. Morgan Annual Healthcare Conference
InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the J.P. Morgan 38th Annual Healthcare Conference being held January 13-16, 2020 at the Westin St. Francis Hotel in San Francisco, CA, USA..
InflaRx Reports Third Quarter 2019 Financial & Operating Results
Recently announced results of open label extension part of SHINE Phase IIb study confirm potential of IFX-1 in Hidradenitis Suppurativa and warrant evaluation of future development
InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa
70.6% of week 16 HiSCR responders maintain response throughout week 40 while 41.8% of non-responders become responders (total HiSCR rate = 56.3% at end of treatment)
InflaRx Reports Second Quarter 2019 Financial & Operating Results
InflaRx reported financial and operating results for the second quarter ended June 30, 2019.
InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
InflaRx reported additional in-depth analysis of the completed double blind, placebo controlled part of the ongoing international SHINE Phase IIb study to supplement InflaRx’s top line disclosure of results reported on June 5, 2019.
InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers
InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
InflaRx reported the top-line results of the international SHINE Phase IIb study, investigating the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in patients suffering from moderate to severe Hidradenitis Suppurativa (HS), a painful and debilitating chronic inflammatory skin disease with limited treatment options.
InflaRx Reports First Quarter 2019 Financial & Operating Results
InflaRx reported financial and operating results for the first quarter ended March 31, 2019.
InflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe
InflaRx today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in patients with ANCA-associated vasculitis (AAV) (NCT03895801).
InflaRx Full Year 2018 Financial & Operating Results
$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1
InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcers
Richard Brudnick to join InflaRx Board of Directors
InflaRx N.V. announced that Mr. Richard Brudnick has been appointed, as interim Non-Executive Director to the Board of Directors of InflaRx N.V.
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatment
InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management
- Jason Marks appointed Chief Legal Officer / General Counsel
InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis
InflaRx N.V. today announced the approval of an Investigational Medicinal Product Dossier (IMPD) from the European regulatory authorities, allowing InflaRx to initiate a phase II study with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).
InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results
• Completion of patient recruitment in phase IIb trial in Hidradenitis Suppurativa • First patient dosed in phase II trial with IFX-1 in ANCA- associated vasculitis • Board of Directors appointment Jens Holstein, Chief Financial Officer of MorphoSys AG